Cantor Fitzgerald slashes price target on Jaguar Health Inc. [JAGX] – find out why.

Jaguar Health Inc. [NASDAQ: JAGX] price plunged by -6.62 percent to reach at $0.0. The company report on December 19, 2022 that Jaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party Investigator.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Jaguar is also supporting a third-party investigator evaluating crofelemer for eosinophilic colitis, another rare pediatric gastrointestinal condition.

Proof-of-concept data for the use of crofelemer for pediatric orphan or rare disorders is expected to provide additional support for the potential for expanded patient access to crofelemer through programs in Europe in late 2023.

A sum of 6120550 shares traded at recent session while its average daily volume was at 3.34M shares. Jaguar Health Inc. shares reached a high of $0.0969 and dropped to a low of $0.085 until finishing in the latest session at $0.09.

The one-year JAGX stock forecast points to a potential upside of 97.75. The average equity rating for JAGX stock is currently 1.50, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Jaguar Health Inc. [JAGX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JAGX shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JAGX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for Jaguar Health Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 07, 2021. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on July 11, 2017, representing the official price target for Jaguar Health Inc. stock.

The Average True Range (ATR) for Jaguar Health Inc. is set at 0.01, with the Price to Sales ratio for JAGX stock in the period of the last 12 months amounting to 1.25. The Price to Book ratio for the last quarter was 2.87, with the Price to Cash per share for the same quarter was set at 0.07.

JAGX Stock Performance Analysis:

Jaguar Health Inc. [JAGX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.77. With this latest performance, JAGX shares dropped by -25.86% in over the last four-week period, additionally sinking by -72.39% over the last 6 months – not to mention a drop of -92.39% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JAGX stock in for the last two-week period is set at 25.61, with the RSI for the last a single of trading hit 20.26, and the three-weeks RSI is set at 29.14 for Jaguar Health Inc. [JAGX]. The present Moving Average for the last 50 days of trading for this stock 0.1265, while it was recorded at 0.0948 for the last single week of trading, and 0.2901 for the last 200 days.

Insight into Jaguar Health Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Jaguar Health Inc. [JAGX] shares currently have an operating margin of -939.05 and a Gross Margin at +46.18. Jaguar Health Inc.’s Net Margin is presently recorded at -1213.26.

Return on Equity for this stock declined to -365.08, with Return on Assets sitting at -109.45.

Jaguar Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.90.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JAGX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Jaguar Health Inc. go to 40.00%.

Jaguar Health Inc. [JAGX] Insider Position Details

There are presently around $0 million, or 3.90% of JAGX stock, in the hands of institutional investors. The top three institutional holders of JAGX stocks are: VANGUARD GROUP INC with ownership of 1,578,735, which is approximately -28.637% of the company’s market cap and around 19.46% of the total institutional ownership; MILLENNIUM MANAGEMENT LLC, holding 857,322 shares of the stock with an approximate value of $74000.0 in JAGX stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $63000.0 in JAGX stock with ownership of nearly -38.483% of the company’s market capitalization.

Positions in Jaguar Health Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 14 institutional holders increased their position in Jaguar Health Inc. [NASDAQ:JAGX] by around 837,409 shares. Additionally, 10 investors decreased positions by around 1,154,307 shares, while 9 investors held positions by with 3,606,479 shares. The mentioned changes placed institutional holdings at 5,598,195 shares, according to the latest SEC report filing. JAGX stock had 7 new institutional investments in for a total of 398,369 shares, while 4 institutional investors sold positions of 54,992 shares during the same period.


Please enter your comment!
Please enter your name here